Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2017 4
2018 8
2019 10
2020 15
2021 11
2022 13
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab for the treatment of multiple sclerosis: a review.
Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Chisari CG, et al. J Neurol. 2022 Jan;269(1):159-183. doi: 10.1007/s00415-020-10362-z. Epub 2021 Jan 8. J Neurol. 2022. PMID: 33416999 Free PMC article. Review.
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis.
De Meo E, Portaccio E, Giorgio A, Ruano L, Goretti B, Niccolai C, Patti F, Chisari CG, Gallo P, Grossi P, Ghezzi A, Roscio M, Mattioli F, Stampatori C, Simone M, Viterbo RG, Bonacchi R, Rocca MA, De Stefano N, Filippi M, Amato MP. De Meo E, et al. Among authors: chisari cg. JAMA Neurol. 2021 Apr 1;78(4):414-425. doi: 10.1001/jamaneurol.2020.4920. JAMA Neurol. 2021. PMID: 33393981 Free PMC article.
Palliative care in multiple sclerosis.
Cimino V, Chisari CG, Toscano S, Patti F. Cimino V, et al. Among authors: chisari cg. Handb Clin Neurol. 2023;191:129-138. doi: 10.1016/B978-0-12-824535-4.00009-4. Handb Clin Neurol. 2023. PMID: 36599504 Review.
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG, Bianco A, Brescia Morra V, Calabrese M, Capone F, Cavalla P, Chiavazza C, Comi C, Danni M, Filippi M, Iaffaldano P, Lanzillo R, Lo Fermo S, Lucisano A, Lugaresi A, Lus G, Marfia GA, Marinelli F, Mirabella M, Moiola L, Perin C, Realmuto S, Toscano S, Trojano M, Vecchio D, Patti F; Italian MS Registry. Chisari CG, et al. Neurotherapeutics. 2023 Oct;20(6):1696-1706. doi: 10.1007/s13311-023-01415-y. Epub 2023 Aug 23. Neurotherapeutics. 2023. PMID: 37610702 Free PMC article.
Pharmacoeconomics of synthetic therapies for multiple sclerosis.
D'Amico E, Chisari CG, Gitto L, Zanghì A, Toscano S, Patti F. D'Amico E, et al. Among authors: chisari cg. Expert Opin Pharmacother. 2019 Aug;20(11):1331-1340. doi: 10.1080/14656566.2019.1615880. Epub 2019 May 15. Expert Opin Pharmacother. 2019. PMID: 31090469 Review.
Multiple Sclerosis, COVID-19 and Vaccines: Making the Point.
Toscano S, Chisari CG, Patti F. Toscano S, et al. Among authors: chisari cg. Neurol Ther. 2021 Dec;10(2):627-649. doi: 10.1007/s40120-021-00288-7. Epub 2021 Oct 8. Neurol Ther. 2021. PMID: 34625925 Free PMC article. Review.
REal-World effectIveNess of claDribine for patients with multiple sclerosis: a Sicilian multicentric experience (REWIND study).
Arena S, Chisari CG, Toscano S, Bucello S, Grimaldi LM, Ragonese P, Realmuto S, Cottone S, Maimone D, Finocchiaro C, Reitano P, Patti F. Arena S, et al. Among authors: chisari cg. Curr Neuropharmacol. 2023 Mar 22;22(7):1271-83. doi: 10.2174/1570159X21666230322140711. Online ahead of print. Curr Neuropharmacol. 2023. PMID: 36946484
67 results